أرسل هذا في رسالة قصيرة: Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

  ______     ___      _  __   __   __   ______   
 /_   _//   / _ \\   | |/ //  \ \\/ // |      \\ 
   | ||    | / \ ||  | ' //    \ ` //  |  --  // 
  _| ||    | \_/ ||  | . \\     | ||   |  --  \\ 
 /__//      \___//   |_|\_\\    |_||   |______// 
 `--`       `---`    `-` --`    `-`'   `------`